XHKG9955
Market cap80mUSD
Dec 27, Last price
1.20HKD
1D
0.84%
1Q
-11.11%
IPO
-95.56%
Name
ClouDr Group Ltd
Chart & Performance
P/E
—
P/S
0.16
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
49.56%
Rev. gr., 5y
66.98%
Revenues
3.69b
+23.51%
Net income
-323m
L-80.87%
CFO
-140m
L-78.15%
Profile
ClouDr Group Limited, an investment holding company, provides supplies and software as a service (SaaS) to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions for chronic condition management. It distributes hospital supplies, which include medical devices, such as blood glucose meters and vital sign monitors, glucose testing strips, and OTC and prescription drugs; and hospital and pharmacy SaaS and digital marketing services to pharmaceutical companies. The company also provides real time consultation, digital condition tracking, and online prescription and ordering services. ClouDr Group Limited was founded in 2014 and is headquartered in Hangzhou, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 3,690,536 23.51% | 2,988,056 70.09% | 1,756,731 109.35% | |||
Cost of revenue | 4,038,156 | 3,579,524 | 2,283,636 | |||
Unusual Expense (Income) | ||||||
NOPBT | (347,620) | (591,468) | (526,905) | |||
NOPBT Margin | ||||||
Operating Taxes | 18 | (1,422) | (2,314) | |||
Tax Rate | ||||||
NOPAT | (347,638) | (590,046) | (524,591) | |||
Net income | (323,065) -80.87% | (1,688,937) -59.19% | (4,138,913) 44.37% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (7,083) | 457,069 | (8,117) | |||
BB yield | 0.19% | -11.34% | ||||
| Debt | ||||||
Debt current | 436,342 | 209,062 | 119,506 | |||
Long-term debt | 65,377 | 50,450 | 13,723 | |||
Deferred revenue | (49,425) | (14,359) | ||||
Other long-term liabilities | 49,425 | 14,359 | ||||
Net debt | (128,377) | (463,663) | (985,346) | |||
| Cash flow | ||||||
Cash from operating activities | (140,430) | (642,631) | (666,333) | |||
CAPEX | (123,029) | (167,236) | (88,683) | |||
Cash from investing activities | (38,341) | (744,941) | (155,497) | |||
Cash from financing activities | 171,814 | 503,548 | 1,015,371 | |||
FCF | (418,553) | (9,111,289) | 3,636,809 | |||
| Balance | ||||||
Cash | 752,961 | 723,175 | 1,118,575 | |||
Long term investments | (122,865) | |||||
Excess cash | 445,569 | 573,772 | 1,030,738 | |||
Stockholders' equity | (9,974,614) | 1,921,703 | (7,155,084) | |||
Invested Capital | 12,209,611 | 1,529,432 | 114,331 | |||
ROIC | 36.30% | |||||
ROCE | 7.50% | |||||
| EV | ||||||
Common stock shares outstanding | 540,820 | 300,298 | 568,038 | |||
Price | 6.85 -48.96% | 13.42 | ||||
Market cap | 3,704,617 -8.07% | 4,029,999 | ||||
EV | 3,516,216 | 3,598,363 | ||||
EBITDA | (239,441) | (479,387) | (440,364) | |||
EV/EBITDA | ||||||
Interest | 10,782 | 8,021 | 9,607 | |||
Interest/NOPBT | ||||||